U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H40O3
Molecular Weight 400.594
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRESTOLONE ENANTHATE

SMILES

[H][C@@]12CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC[C@]3([H])[C@@]4([H])CCC(=O)C=C4C[C@@H](C)[C@@]23[H]

InChI

InChIKey=YHLLSSBURKVUEG-YFGHHJRWSA-N
InChI=1S/C26H40O3/c1-4-5-6-7-8-24(28)29-23-12-11-22-25-17(2)15-18-16-19(27)9-10-20(18)21(25)13-14-26(22,23)3/h16-17,20-23,25H,4-15H2,1-3H3/t17-,20+,21-,22+,23+,25-,26+/m1/s1

HIDE SMILES / InChI

Molecular Formula C26H40O3
Molecular Weight 400.594
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 7
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Trestolone is a synthetic androgen that inhibits the release of follicle-stimulating hormone and impairs spermatogenesis. Luteinizing hormone is also suppressed, which cuts production of testosterone. The azoospermia and oligospermia are reversible after discontinuation of trestolone. Trestolone has androgenic and anabolic properties and loss of secondary sex characteristics is not seen. Like testosterone, trestolone undergoes enzymatic aromatization to an estrogen. The use of trestolone instead of testosterone for androgen replacement therapy could have health-promoting effects by reducing the occurrence of prostate disease. Trestolone had been in phase II clinical trial for the andropause control. However, this development was discontinued.

Originator

Approval Year

PubMed

Substance Class Chemical
Record UNII
2UJ2UPS5XU
Record Status Validated (UNII)
Record Version